ASCO 2016 highlights for CLL
Updates from the CLL14 and CLL2-GiVe trials on CLL
2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
Current treatment landscape of myeloma
Changing the way we treat multiple myeloma based on biological markers in 2016